NRx Pharmaceuticals' (NRXP) "Buy" Rating Reaffirmed at HC Wainwright

Key Points

• NRx Pharmaceuticals' stock has been reaffirmed with a "buy" rating by HC Wainwright, with a target price set at $40.00.
• The company has an average rating of "Moderate Buy" among analysts, with a consensus target price of $34.50 reflecting mixed ratings from various research firms.
• NRx Pharmaceuticals recently reported an earnings miss, posting a loss of ($0.98) EPS, significantly below analysts' expectations.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $40.00 target price on the stock.

NRXP has been the topic of a number of other reports. Zacks Research raised shares of NRx Pharmaceuticals to a "hold" rating in a research report on Wednesday, September 10th. BTIG Research reissued a "buy" rating on shares of NRx Pharmaceuticals in a research report on Monday, August 25th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of NRx Pharmaceuticals in a report on Wednesday, October 8th. Finally, D. Boral Capital restated a "buy" rating and set a $34.00 target price on shares of NRx Pharmaceuticals in a research note on Thursday, September 25th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $34.50.

NRx Pharmaceuticals Stock Performance

Shares of NRx Pharmaceuticals stock opened at $3.17 on Thursday. The company has a fifty day moving average of $2.87 and a 200-day moving average of $2.72. NRx Pharmaceuticals has a 52-week low of $1.10 and a 52-week high of $6.01. The stock has a market capitalization of $62.80 million, a price-to-earnings ratio of -1.42 and a beta of 1.74.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last posted its quarterly earnings results on Monday, August 18th. The company reported ($0.98) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.67). On average, equities research analysts forecast that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in NRx Pharmaceuticals stock. Anson Funds Management LP lifted its holdings in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Free Report) by 535.1% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,179,061 shares of the company's stock after purchasing an additional 993,401 shares during the quarter. Anson Funds Management LP owned 6.82% of NRx Pharmaceuticals worth $2,417,000 at the end of the most recent quarter. 4.27% of the stock is currently owned by institutional investors and hedge funds.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.